Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Local Anesthetics: Differential Sensitivity of Nerve Fibers01:24

Local Anesthetics: Differential Sensitivity of Nerve Fibers

866
Local anesthetics (LAs) block the sodium channels of nerve trunks, sensory nerve endings, and neuromuscular junctions. Although LAs can block all kinds of nerves, the sensitivity of nerve fibers differs according to nerve types and structures. LAs are known to block myelinated fibers faster than unmyelinated ones. Also, they block pain or sensory neurons at low concentrations without affecting the motor neurons involved in muscle contractions. This helps relieve labor pain without affecting the...
866
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

1.1K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.1K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

1.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.6K
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

567
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
567
G-Protein Gated Ion Channels01:21

G-Protein Gated Ion Channels

4.6K
GPCRs are primarily responsible for our sense of smell, taste, and vision.  The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
4.6K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

560
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
560

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trigeminovascular calcitonin gene-related peptide release and peripheral vascular responses in a mouse model of accelerated aging: Implications for migraine.

The journal of headache and pain·2026
Same author

Longitudinal Maternal IgG and IgA Glycosylation Profiles in Pregnancy Reveal Early Immune Alterations in Placenta-Related Complications: The Rotterdam Periconception Cohort.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

AMPK-mediated prevention of vascular dysfunction with metformin: Experimental and population-based evidence.

British journal of pharmacology·2026
Same author

Correction: What's a migraine day? Towards a consensus definition for clinical care and research - a Delphi panel-based study.

The journal of headache and pain·2026
Same author

Aortic stiffness and cardiac function in middle-aged women with ischemic stroke with and without migraine.

BMC neurology·2026
Same author

Pharmacological mechanisms underlying neurovascular alterations related to resistant and refractory migraine: CGRP pathways and beyond.

The journal of headache and pain·2026
Same journal

RETRACTED: Sobeh et al. A Polyphenol-Rich Fraction from <i>Eugenia uniflora</i> Exhibits Antioxidant and Hepatoprotective Activities In Vivo. <i>Pharmaceuticals</i> 2020, <i>13</i>, 84.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Correction: Jiménez-Sánchez et al. Antioxidant Enzymes Genetic Variants Associated with Urticaria/Angioedema Induced by Cross-Reactive Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs. <i>Pharmaceuticals</i> 2026, <i>19</i>, 522.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Correction: Zhao et al. Multifunctional Gel Films of Marine Polysaccharides Cross-Linked with Poly-Metal Ions for Wound Healing. <i>Pharmaceuticals</i> 2022, <i>15</i>, 750.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Intravenous Immunoglobulin Reveals a Novel Protective Mechanism: Targeting the GBP5-Driven Pyroptosis Axis in Experimental Colitis.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Icariin Attenuates Renal Injury in Streptozotocin-Induced Diabetic Rats with and Without Adenine-Induced Chronic Kidney Disease.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

AI-Assisted Identification of a Putative Allosteric Ligand Targeting the CDK4/Cyclin D1 Protein-Protein Interface.

Pharmaceuticals (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: Jul 18, 2025

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
08:39

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Published on: May 16, 2022

2.4K

Blocking the CGRP Receptor: Differences across Human Vascular Beds.

Tessa de Vries1, Deirdre M Boucherie1, Antoon van den Bogaerdt2

  • 1Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.

Pharmaceuticals (Basel, Switzerland)
|August 26, 2023
PubMed
Summary
This summary is machine-generated.

Zavegepant, a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist, demonstrated similar potency in human coronary and middle meningeal arteries. This finding is crucial for assessing the cardiovascular safety of new migraine treatments.

Keywords:
CGRPSchild plotantagonismgepantsmigrainepotencyvasodilation

More Related Videos

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay
07:14

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay

Published on: June 16, 2023

2.7K
Visualizing the Calcitonin Gene-Related Peptide Immunoreactive Innervation of the Rat Cranial Dura Mater with Immunofluorescence and Neural Tracing
07:28

Visualizing the Calcitonin Gene-Related Peptide Immunoreactive Innervation of the Rat Cranial Dura Mater with Immunofluorescence and Neural Tracing

Published on: January 6, 2021

4.1K

Related Experiment Videos

Last Updated: Jul 18, 2025

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
08:39

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Published on: May 16, 2022

2.4K
Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay
07:14

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay

Published on: June 16, 2023

2.7K
Visualizing the Calcitonin Gene-Related Peptide Immunoreactive Innervation of the Rat Cranial Dura Mater with Immunofluorescence and Neural Tracing
07:28

Visualizing the Calcitonin Gene-Related Peptide Immunoreactive Innervation of the Rat Cranial Dura Mater with Immunofluorescence and Neural Tracing

Published on: January 6, 2021

4.1K

Area of Science:

  • Pharmacology
  • Cardiovascular Research
  • Neuroscience

Background:

  • Migraine treatments increasingly target the calcitonin gene-related peptide (CGRP) pathway.
  • Understanding the effects of CGRP receptor antagonists on cardiovascular tissues is vital for drug safety.

Purpose of the Study:

  • To investigate the effect of zavegepant on CGRP-induced relaxation in human coronary arteries (HCAs).
  • To compare the potency of several CGRP receptor antagonists, including zavegepant, in HCAs and human middle meningeal arteries (HMMAs).

Main Methods:

  • Isolated human coronary arteries were used to assess CGRP-induced relaxation in the presence of zavegepant.
  • Schild plot analysis was employed to determine the potency (pA2 value) and mechanism of action of zavegepant.
  • Data from previous studies on other antagonists (atogepant, olcegepant, rimegepant, telcagepant, ubrogepant) in HCAs and HMMAs were compared with zavegepant's effects.

Main Results:

  • Zavegepant exhibited a pA2 value of 9.92 ± 0.24 in HCAs, with a Schild plot slope not significantly different from unity.
  • Zavegepant showed similar potency in both HCAs and HMMAs.
  • Antagonists with Schild slopes < 1 were more potent in HMMAs, while those with slopes near unity (like zavegepant) showed consistent potency across both artery types.

Conclusions:

  • Zavegepant acts as a CGRP receptor antagonist with consistent potency in both coronary and meningeal arteries.
  • A Schild plot slope < 1 suggests potential involvement of multiple receptors in CGRP-mediated relaxation in HCAs.
  • Further research into HCAs' CGRP receptor pharmacology is recommended to enhance the cardiovascular safety profile of future migraine therapeutics.